Surgalign Holdings, Inc. (SRGA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Surgalign Holdings, Inc. (SRGA) Healthcare & Pipeline Overview

Surgalign Holdings, Inc. specializes in spine implants and digital surgery platforms, offering a range of products for thoracolumbar and cervical procedures. With a focus on innovation and minimally invasive solutions, the company serves hospitals, ambulatory surgery centers, and healthcare providers through distributors and a direct sales force.

What Is the Investment Thesis for SRGA?

Surgalign Holdings, Inc. operates in the spine implant market, which is characterized by ongoing technological advancements and a growing demand for minimally invasive surgical solutions. The company's focus on developing Augmented Reality and Artificial Intelligence digital surgery platforms presents a potential growth catalyst, positioning it to capitalize on the increasing adoption of digital technologies in spine surgery. However, Surgalign's negative profit margin of -66.6% indicates significant challenges in achieving profitability. The company's success hinges on its ability to effectively commercialize its innovative products, manage its operating expenses, and navigate the competitive landscape. Investors should closely monitor Surgalign's progress in improving its financial performance and gaining market share in the spine implant market.

Based on FMP financials and quantitative analysis

SRGA Key Highlights

Surgalign Holdings, Inc. operates with 217 employees, indicating a relatively lean operational structure.

• The company's gross margin stands at 49.1%, reflecting its ability to generate revenue above the direct costs of its products.
• Surgalign has a beta of 1.80, suggesting a higher volatility compared to the overall market.
• Surgalign's profit margin is -66.6%, indicating that the company is currently operating at a loss.
• Surgalign does not offer a dividend, which is typical for growth-oriented companies reinvesting earnings.

Who Are SRGA's Competitors?

SRGA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SRGA's Key Strengths?

Innovative product portfolio, including digital surgery platforms.

• Focus on minimally invasive surgical solutions.
• Established distribution network.
• Expertise in spine implant design and manufacturing.

What Are SRGA's Weaknesses?

Negative profit margin.

• High beta indicating volatility.
• Limited financial resources compared to larger competitors.
• Dependence on regulatory approvals for new products.

What Could Drive SRGA Stock Higher?

Regulatory approvals for Augmented Reality and Artificial Intelligence digital surgery platform.

• Expansion of distribution network in key markets.
• Development and launch of new spine implant products.

What Are the Key Risks for SRGA?

Financial-distress signal — its Altman Z-Score of -14.13 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Delays in regulatory approvals for new products.
• Intense competition from established medical device companies.
• Product liability claims.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for SRGA?

• Augmented Reality and Artificial Intelligence Digital Surgery Platform: Surgalign's development of Augmented Reality and Artificial Intelligence digital surgery platforms represents a significant growth opportunity. Surgalign's platform has the potential to improve surgical outcomes, reduce complications, and enhance the overall efficiency of spine surgery. The company's ability to secure regulatory approvals and establish partnerships with healthcare providers will be crucial for realizing this growth opportunity.
• Expansion of Minimally Invasive Surgery (MIS) Solutions: The market for minimally invasive spine surgery is growing due to benefits such as reduced recovery times and less post-operative pain. Surgalign's Streamline MIS Spinal Fixation system positions it to capitalize on this trend. As healthcare providers increasingly adopt MIS techniques, Surgalign can expand its market share by offering innovative MIS solutions and providing training and support to surgeons. The company's ability to differentiate its MIS products through technological advancements and clinical evidence will be key to its success.
• Geographic Expansion: Surgalign currently markets its products worldwide, but there is potential for further geographic expansion, particularly in emerging markets. The increasing prevalence of spinal disorders and the growing healthcare infrastructure in countries like China and India present opportunities for Surgalign to increase its sales and market share. The company's ability to adapt its products to local market needs, establish distribution networks, and navigate regulatory requirements will be critical for successful geographic expansion.
• Strategic Partnerships and Acquisitions: Surgalign can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and gain access to new markets. Collaborating with other medical device companies, technology providers, or research institutions can accelerate innovation and improve Surgalign's competitive position. Acquisitions of complementary businesses can provide Surgalign with new products, technologies, or distribution channels. The company's ability to identify and integrate strategic partnerships and acquisitions will be important for driving long-term growth.
• Focus on Motion Preservation Technologies: The market for motion preservation technologies, such as the Coflex Interlaminar Stabilization device, is growing as surgeons seek alternatives to traditional spinal fusion procedures. Surgalign's focus on motion preservation technologies positions it to capitalize on this trend. By offering innovative motion preservation solutions and demonstrating their clinical benefits, Surgalign can attract surgeons and patients seeking less invasive and more functional treatment options. The company's ability to generate clinical evidence and educate healthcare providers about the benefits of motion preservation will be crucial for its success.

What Are SRGA's Competitive Advantages?

• Proprietary spine implant designs.
• Augmented Reality and Artificial Intelligence digital surgery platform.
• Established distribution network.
• Focus on minimally invasive surgical solutions.

What Does SRGA Do?

Surgalign Holdings, Inc., established in 1997 and headquartered in Deerfield, Illinois, is a medical technology company focused on developing, manufacturing, and distributing spine implants worldwide. The company's product portfolio includes solutions for thoracolumbar procedures, such as the Streamline TL Spinal Fixation system designed for degenerative and complex spine cases, and the Streamline MIS Spinal Fixation system, catering to percutaneous or mini-open approaches. Surgalign also offers interbody fusion devices and products for cervical procedures, including the CervAlign ACP system, Fortilink-C IBF system utilizing TETRAfuse 3D technology, and the Streamline OCT system for occipito-cervico-thoracic posterior spine procedures. Furthermore, Surgalign provides motion preservation systems like the Coflex Interlaminar Stabilization device for lumbar spinal stenosis treatment, the HPS 2.0 Universal Fixation system for thoracolumbar spine stabilization, and the SImmetry SI Joint Fusion system, a minimally invasive solution aimed at reducing opioid use and pain. A key aspect of Surgalign's strategy involves the development of Augmented Reality and Artificial Intelligence digital surgery platforms, aimed at transforming spine surgery through advanced technology. The company markets its products through a network of independent spine and biomaterial distributors, as well as a direct sales force, targeting hospitals, ambulatory surgery centers, and healthcare providers globally.

What Products and Services Does SRGA Offer?

• Develops and manufactures spine implants.
• Distributes spine implants globally.
• Offers products for thoracolumbar procedures.
• Provides solutions for cervical procedures.
• Develops motion preservation systems.
• Creates Augmented Reality and Artificial Intelligence digital surgery platforms.
• Markets products through distributors and direct sales force.

How Does SRGA Make Money?

• Develops and manufactures spine implants and related surgical tools.
• Sells products to hospitals, ambulatory surgery centers, and healthcare providers.
• Utilizes a direct sales force and independent distributors to reach customers.
• Generates revenue through product sales and related services.

What Industry Does SRGA Operate In?

Surgalign Holdings, Inc. operates within the medical device industry, specifically focusing on spine implants and digital surgery solutions. The spine implant market is driven by factors such as an aging population, increasing prevalence of spinal disorders, and advancements in surgical techniques. The industry is competitive, with established players and emerging companies vying for market share. Surgalign's focus on Augmented Reality and Artificial Intelligence digital surgery platforms aligns with the growing trend of incorporating digital technologies into surgical procedures. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products in a competitive landscape.

Who Are SRGA's Key Customers?

• Hospitals
• Ambulatory surgery centers
• Healthcare providers
• Spine surgeons

Key Financial Metrics

Return on assets is -77.7%, showing how much profit it generates from its asset base. A current ratio of 2.68 indicates the company holds enough short-term assets to cover its near-term obligations.

Surgalign Holdings, Inc. (SRGA) Valuation Context

Relative to its peer group, SRGA's quantitative score of 45/100 is below the peer average of 72/100.

Company Profile

Surgalign Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Deerfield, US. The company is led by CEO Terry M. Rich. SRGA has traded publicly since 2000.

Surgalign Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.13 places it in the distress zone, a signal of elevated financial risk.

The most recent 12 insider filings for Surgalign Holdings, Inc. break down as 12 sales and 0 purchases. On net that is roughly 35K shares disposed (about $2K), a signal worth weighing alongside the fundamentals.

SRGA Financials

SRGA Latest News

No recent news available for SRGA.

SRGA Analyst Consensus

SRGA MoonshotScore

Surgalign Holdings, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources